Literature DB >> 25650316

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.

Aimée R Kreimer1, Mark E Sherman2, Vikrant V Sahasrabuddhe2, Mahboobeh Safaeian2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25650316      PMCID： PMC4326307          DOI： 10.1093/jnci/dju436

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  22 in total

1.  A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

2.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Bradley Fox; Sofia Scholar; Jeffrey Rosen; Nahida Chakhtoura; Dorothée Meric; Francis J Dessy; Sanjoy K Datta; Dominique Descamps; Gary Dubin
Journal:  Hum Vaccin       Date:  2011-12-01

3.  Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Authors:  Eva Herweijer; Amy Leval; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström
Journal:  JAMA       Date:  2014-02-12       Impact factor: 56.272

4.  Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Authors:  Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young
Journal:  JAMA       Date:  2013-05-01       Impact factor: 56.272

5.  Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim
Journal:  Cancer Discov       Date:  2011-09-09       Impact factor: 39.397

6.  Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2013-11

Review 7.  Global burden of human papillomavirus and related diseases.

Authors:  David Forman; Catherine de Martel; Charles J Lacey; Isabelle Soerjomataram; Joannie Lortet-Tieulent; Laia Bruni; Jerome Vignat; Jacques Ferlay; Freddie Bray; Martyn Plummer; Silvia Franceschi
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

8.  Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-07-26       Impact factor: 17.586

9.  Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

Authors:  Elizabeth Crowe; Nirmala Pandeya; Julia M L Brotherton; Annette J Dobson; Stephen Kisely; Stephen B Lambert; David C Whiteman
Journal:  BMJ       Date:  2014-03-04

10.  Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Authors:  Dorota M Gertig; Julia M L Brotherton; Alison C Budd; Kelly Drennan; Genevieve Chappell; A Marion Saville
Journal:  BMC Med       Date:  2013-10-22       Impact factor: 8.775
View more
  10 in total

1.  Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Authors:  Mahboobeh Safaeian; Joshua N Sampson; Yuanji Pan; Carolina Porras; Troy J Kemp; Rolando Herrero; Wim Quint; Leen Jan van Doorn; John Schussler; Douglas R Lowy; John Schiller; Mark T Schiffman; Ana Cecilia Rodriguez; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto; Aimée R Kreimer
Journal:  J Natl Cancer Inst       Date:  2018-02-01       Impact factor: 13.506

Review 2.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

3.  Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Authors:  Aimée R Kreimer; Frank Struyf; Maria Rowena Del Rosario-Raymundo; Allan Hildesheim; S Rachel Skinner; Sholom Wacholder; Suzanne M Garland; Rolando Herrero; Marie-Pierre David; Cosette M Wheeler; Paula González; Silvia Jiménez; Douglas R Lowy; Ligia A Pinto; Caroline Porras; Ana Cecilia Rodriguez; Mahboobeh Safaeian; Mark Schiffman; John T Schiller; John Schussler; Mark E Sherman; F Xavier Bosch; Xavier Castellsague; Archana Chatterjee; Song-Nan Chow; Dominique Descamps; Francisco Diaz-Mitoma; Gary Dubin; Maria Julieta Germar; Diane M Harper; David J M Lewis; Genara Limson; Paulo Naud; Klaus Peters; Willy A J Poppe; Brian Ramjattan; Barbara Romanowski; Jorge Salmeron; Tino F Schwarz; Julio C Teixeira; Wiebren A A Tjalma
Journal:  Lancet Oncol       Date:  2015-06-09       Impact factor: 41.316

4.  National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Authors:  David P Durham; Martial L Ndeffo-Mbah; Laura A Skrip; Forrest K Jones; Chris T Bauch; Alison P Galvani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

5.  JC polyomavirus mutants escape antibody-mediated neutralization.

Authors:  Upasana Ray; Paola Cinque; Simonetta Gerevini; Valeria Longo; Adriano Lazzarin; Sven Schippling; Roland Martin; Christopher B Buck; Diana V Pastrana
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

6.  Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population.

Authors:  Carmen Radecki Breitkopf; Lila J Finney Rutten; Victoria Findley; Debra J Jacobson; Patrick M Wilson; Monica Albertie; Robert M Jacobson; Gerardo Colón-Otero
Journal:  Cancer Med       Date:  2016-10-17       Impact factor: 4.452

7.  Adolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing?

Authors:  Jennifer Cunningham Erves; Tilicia L Mayo-Gamble; Pamela C Hull; Lauren Duke; Stephania T Miller
Journal:  J Community Health       Date:  2017-10

8.  An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses.

Authors:  Vicky Gent; Rebecca Waihenya; Lucy Kamau; Ruth Nyakundi; Peris Ambala; Thomas Kariuki; Lucy Ochola
Journal:  PLoS Negl Trop Dis       Date:  2019-08-26

Review 9.  Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Authors:  Marc Arbyn; Lan Xu; Cindy Simoens; Pierre Pl Martin-Hirsch
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

10.  A Vaccine Against Cervical Cancer: Context for the Global Public Health Practitioner.

Authors:  Mary Carol Jennings; Anagha Loharikar
Journal:  Glob Health Sci Pract       Date:  2018-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.